New York, NY (PRWEB) January 11, 2014
As Tylenol lawsuits (http://www.tylenollawsuitclaims.com/)
involving liver damage allegations continue to move forward in courts around the U.S., Bernstein Liebhard LLP notes that new limits regarding the amount of acetaminophen allowed in prescription medications are set to go into effect this month. According to a notice published by the U.S. Food & Drug Administration (FDA) on the Federal Registry, the amount of acetaminophen allowed in prescription drugs is being reduced to 325 mg per tablet or capsule to lessen the risk of liver damage associated with acetaminophen overdose.*
“Dozens of Tylenol lawsuits have been filed on behalf of consumers who allegedly suffered acetaminophen liver damage, even when these products were used as directed,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free Tylenol lawsuit reviews to victims of severe liver damage allegedly associated with the use of Tylenol-brand medications.
Tylenol and Liver Damage
The FDA reported in 2009 that acetaminophen, the active ingredient in over-the-counter drugs sold under the Tylenol brand name, was the leading cause of acute liver failure in the U.S. between 1998 and 2003. From 1990 to 1998, acetaminophen was blamed for 56,000 emergency room visits, 26,000 hospitalizations, and 458 deaths annually.
According to a Bloomberg.com report published last summer, Extra Strength Tylenol caplets each contain 500 mg of acetaminophen, well over the new limits set by the FDA. According to the report, Johnson & Johnson is in the process of adding more prominent warnings regarding the risk of liver damage to the labels of Tylenol-brand medications. Bottles of Extra Strength Tylenol began to appear with the new label warnings this past October, while other medications in the line are expected to follow.**
Court documents indicate that nearly 100 Tylenol lawsuits involving liver damage allegations are currently pending in a federal multidistrict litigation underway in U.S. District Court, Eastern District of Pennsylvania. All of these lawsuits similarly allege that Johnson & Johnson failed to provide consumers with adequate warnings about the potential effects of acetaminophen use on the liver, including liver failure and the need for a liver transplant. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
Victims of liver damage allegedly associated with the use of a Tylenol product may be entitled to compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Tylenol lawsuit, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 for a free case review.
*federalregister.gov/articles/2011/01/14/2011-709/prescription-drug-products-containing-acetaminophen-actions-to-reduce-liver-injury-from, Federal Registry, January 2014
**bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP